Article Information
History
- March 27, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Bruna G.G. Pinto1,
- Antonio E.R. Oliveira1,
- Youvika Singh1,
- Leandro Jimenez1,
- Andre N A. Gonçalves1,
- Rodrigo L.T. Ogava1,
- Rachel Creighton2,
- Jean Pierre Schatzmann Peron3,4 and
- Helder I. Nakaya1,4,*
- 1Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil
- 2Department of Bioengineering, University of Washington, Seattle, WA, USA
- 3Neuroimmune Interactions Laboratory – Department of Immunology – Institute of Biomedical Sciences - University of Sao Paulo, Sao Paulo, Brazil. CEP 05508-000
- 4Scientific Platform Pasteur USP, São Paulo, Brazil
- ↵*Corresponding author Corresponding author information:
Helder I Nakaya, PhD, Av. Prof. Lúcio Martins Rodrigues, 370, block C, 4th floor, São Paulo – SP - Brazil, CEP: 05508-020, Phone: + 55 11 2648-1130, e-mail: hnakaya{at}usp.br
Posted March 27, 2020.
ACE2 Expression is Increased in the Lungs of Patients with Comorbidities Associated with Severe COVID-19
